Pharsight

Adrenaclick generic

Adrenaclick is a medication owned by Impax. This drug contains the active ingredient epinephrine and is available in injectable; intramuscular, subcutaneous dosage forms. Adrenaclick was first authorized for market use on 30 May, 2003.

When will Adrenaclick generic be available?

The generic versions of Adrenaclick can potentially be released after the expiry of the last patent on 12 April, 2027. This release date is based on the expiration dates of the patents held by Impax for Adrenaclick.

Adrenaclick uses

Adrenaclick, containing epinephrine, is primarily used for emergencies to treat severe allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs, and other allergens. epinephrine works by relaxing the muscles in the airways and tightening the blood vessels, which helps to reverse severe allergic reactions.

Adrenaclick patent expiration

Adrenaclick, owned by Impax, holds a total of four patents. The expiry dates of these patents range from 2025 to 2027, with the last one expiring on 12 April, 2027. Consequently, the generic release date for Adrenaclick will likely be after this date. Below are the details of the patents:

Adrenaclick dosage

Want to ask something?